Resmed’s high margin and recurrent-revenue segment are the core attractions of its business. On margins, the outlook is positive Resmed’s improved update on sales costs and a proposed reduction in headcount. The impact of GLP-1 drugs on the sleep disorder device industry are overly pessimistic, but could deliver continued short term pain as the market factor in their impacts.
Resmed’s high margin and recurrent-revenue segment are the core...
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$32.82 |
Change
0.240(0.74%) |
Mkt cap ! $20.39B | |||
| Open | High | Low | Value | Volume |
| $32.85 | $32.97 | $32.73 | $86.04M | 2.626M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 1353 | $32.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $32.83 | 2348 | 17 |
View Market Depth
| Last trade - 13.12pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$32.90 |
Change
0.240 ( 1.09 %) |
||||
| Open | High | Low | Volume | ||
| $32.85 | $32.96 | $32.74 | 313137 | ||
| Last updated 13.31pm 30/04/2024 ? | |||||
| RMD (ASX) Chart |